outperform core growth
strong initi guid
total revenu y/i fx well ahead
estim organ growth vs estimate
beat broad-bas end-market product categori segment
well ahead forecast gross opmargin came bit light
larg due fx shift mix adj ep street est
strong beat larg expect given peer result recent bullish commentari
better even bullish expect scope breadth beat
well clean natur non-oper item tax rate share count
net interest expens in-lin forecast combin make anoth
strong quarter first look detail result
guid leav upsid market ripe shine
initi organ sale guid in-lin expect given
comp adj ep guid includ dilut
recent anatom patholog sale well fx tariff
said view initi guid like conserv given tmo key end-
market thrive despit persist concern china slowdown macro
environ china organ growth moreov
continu captur share outgrow market multipl busi line
addit upsid potenti futur capit deploy given
compani rapidli de-lever exit net debt trail
adjust ebitda reiter buy rate share
rais estim increas po
estim sale y/i organ fx
 adj ep y/i incl ap sale
sale organ yoy adj ep yoy
new po still dcf base wacc due higher
impli market return termin growth rate improv metric
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
thermo fisher scientif largest
consist analyt instrument lab
equip consum softwar servic
use throughout research drug manufactur
diagnost food consum product safeti
environment test
thermo fisher scientif largest life scienc
tool compani think recent acquisit
complementari technolog higher growth
on-going process improv initi
expand footprint emerg appli
market help grow revenu steadili
line even modestli better
overal tool market deliv low teen ep
compound-annual-growth-rate next sever year
po base dcf model assum wacc termin
growth rate impli multipl approxim ep estim in-lin
compani peer group averag given size market leadership matur
stabil compani consum focus busi believ dcf
appropri way valu compani risk price object deal
integr risk lower-than-expect deal synergi slower growth emerg
market price eros lower healthcar util trend soft uptak new
product competit weak fund
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
